<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361072</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/486/2017</org_study_id>
    <nct_id>NCT03361072</nct_id>
  </id_info>
  <brief_title>The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults</brief_title>
  <official_title>The Effect of Per Oral Immunotherapy Treatment in Severe IgE Mediated Milk, Peanut and Egg Allergy in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut
      or egg allergy in adults. This is the second part of the oral immunotherapy study in adults
      at Skin and Allergy Hospital. The diagnosis of food allergy is verified with positive
      history, skin prick tests, egg and milk allergen specific IgE (immunoglobulin E) antibodies.
      In addition, food allergy is verified with an open label (milk allergy) or blind (peanut and
      egg allergy) allergen specific challenge test. OIT (oral immunotherapy) is performed
      according to a detailed plan. Lung function parameters are followed before OIT and and a year
      after OIT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 patients with milk allergy (at least 18 year olds), 30 patients with peanut allergy and 30
      patients with egg allergy are treated with OIT. The diagnosis of food allergy is verified
      with positive history, skin prick test, egg and milk allergen specific IgE antibodies. In
      addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg
      allergy) allergen specific challenge test. Quality of life, anxiety and patient history data
      is collected by questionnaires. All the patients undergo a spirometry with a bronchodilatator
      test, exhaled nitric oxide test and a methacholine challenge before and a year after oral
      immunotherapy. All the patients undergoing oral immunotherapy are prescribed with emergency
      medication such as antihistamine tablets, prednisolon tablets (40mg for three days in
      adults), epinephrine autoinjector (300 µg per dose) and salbutamol or terbutaline inhalator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective open label study on oral immunotherapy with either milk, or peanut or egg white food products.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desensitisation</measure>
    <time_frame>1 year, through study completion</time_frame>
    <description>Increase in tolerated dose of food compared to the pre-OIT, number of participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in worries associated with food allergy</measure>
    <time_frame>1 year, through study completion</time_frame>
    <description>Quality of life and reported concerns and worries associated with food allergy using a VAS scale 0-100 mm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>1 year, through study completion</time_frame>
    <description>Follow-up of safety of OIT</description>
  </other_outcome>
  <other_outcome>
    <measure>Decrease in allergen specific IgE values</measure>
    <time_frame>1 year, through study completion</time_frame>
    <description>Decrease in allergen specific IgE values</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Milk allergy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Milk oral immunotherapy intervention for milk allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peanut allergy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peanut oral immunotherapy intervention for peanut allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egg allergy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Egg oral immunotherapy intervention for egg allergy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral immunotherapy</intervention_name>
    <description>Milk, peanut or egg oral immunotherapy</description>
    <arm_group_label>Milk allergy</arm_group_label>
    <arm_group_label>Peanut allergy</arm_group_label>
    <arm_group_label>Egg allergy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe milk, peanut or egg allergy verified with positive symptom history, skin prick
             tests and serum IgE tests and a challenge test

        Exclusion Criteria:

          -  instable cerebrovascular or heart disease, active autoimmune disease or cancer, or
             current use of betablockers.

          -  poorly controlled asthma or FEV1 &lt; 70% (FEV1&lt; -2SD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Kauppi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Kauppi, MD, PhD</last_name>
    <phone>+358504286802</phone>
    <email>paula.kauppi@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula M Kauppi</last_name>
      <email>paula.kauppi@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Mika J Mäkelä</last_name>
      <email>mika.makela@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Paula Kauppi, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD, Chief Specialist</investigator_title>
  </responsible_party>
  <keyword>oral immunotherapy</keyword>
  <keyword>milk</keyword>
  <keyword>peanut</keyword>
  <keyword>egg</keyword>
  <keyword>adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Egg Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

